INFO & CONTACTS:  +39 02 2390 1

KEYMAKER-U01 Substudy 01H: A Phase 2, Randomized, Umbrella Study With Rolling Arms of Investigational Agents in Participants with Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC)

Phase: Phase II-III clinical trials

Principal Investigator: Dott. Lo Russo Giuseppe

Main Facility: Oncologia Medica Toraco-Polmonare

Drug: R-DXd (raludotatug deruxtecan)

I-DXd (ifinatamab deruxtecan)

Docetaxel

Pathologies: Lung cancer

ClinicalTrials.gov: Read more about clinical trials

Participants will be randomized into one of three groups: 

  • Group 1: will receive R-DXd (raludotatug deruxtecan) 
  • Group 2: will receive I-DXd (ifinatamab deruxtecan) 
  • Group 3: will receive docetaxel 

Last update: 20/04/2026

Subscribe to the newsletter

Sign up for our newsletter to stay informed about news, events, and updates from the Institute

Subscribe